Wednesday, February 21, 2018
 
 
Company News: Page (1) of 1 - 02/13/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Ionis Pharmaceuticals to Hold 2017 Financial Results Conference Call
Webcast scheduled for Tuesday, February 27 at 11:30 a.m. Eastern Time
(February 13, 2018)

CARLSBAD, Calif., Feb. 13, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesday, February 27 at 11:30 a.m. Eastern Time to discuss its 2017 financial results and report on pipeline and business progress.

Ionis Pharmaceuticals (PRNewsFoto/Ionis Pharmaceuticals, Inc.)

Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.ionispharma.com. A webcast replay will be available for a limited time at the same address.



ABOUT IONIS PHARMACEUTICALS, INC.
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over three dozen drugs in development. SPINRAZA® (nusinersen) has been approved in global markets for the treatment of spinal muscular atrophy (SMA). Biogen is responsible for commercializing SPINRAZA. Drugs that have successfully completed Phase 3 studies include inotersen, an antisense drug Ionis is developing to treat patients with hereditary TTR amyloidosis (hATTR), and volanesorsen, an antisense drug discovered by Ionis and co-developed by Ionis and Akcea Therapeutics to treat patients with either familial chylomicronemia syndrome or familial partial lipodystrophy. Akcea, an affiliate of Ionis, is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. If approved, volanesorsen will be commercialized through Ionis' affiliate, Akcea. Inotersen filings for marketing approval are under review in the U.S. and EU. Volanesorsen filings for marketing approval are under review in the U.S., EU, and Canada. Ionis' patents provide strong and extensive protection for its drugs and technology. Additional information about Ionis is available at www.ionispharma.com.

IONIS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Ionis Pharmaceuticals' financial position and outlook, Ionis' business, the business of Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, and the therapeutic and commercial potential of Ionis' technologies and products in development, including SPINRAZA, inotersen and volanesorsen. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2016, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries.

Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc. SPINRAZA® is a registered trademark of Biogen.

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-hold-2017-financial-results-conference-call-300597474.html

SOURCE Ionis Pharmaceuticals, Inc.

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:USA, Inc.,Medicine,Surgery,Medication,Science,Medical,Business,Other,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • SourceLink Partners with MassMedia Health to Provide Medicare Age-In Data to Healthcare Groups
  • Global Probiotics Industry
  • Global Brain Monitoring Devices Industry
  • Microbubbles/Ultrasound Contrast Agents Market Worth 1,584.5 Million USD by 2024, Says Meticulous Research™
  • Rehabilitation Equipment Market To Witness Enhanced Demand From Hospitals & Clinics, Home Care And Rehabilitation Centers Till 2022 | Million Insights

    Cancer
  • Bolivian Government Invests in State-of-the-art Cancer Care From Elekta
  • 2018 Global Endometriosis Strategic Business Report - Developing Regions Exhibit Immense Growth Potential
  • Cannabics Pharmaceuticals Hires Chief Data Officer to Address Industry Compliance and Utilization/Analytics Application
  • OWC Pharmaceutical Research Corp. Appoints Dr. Oron Yacoby Zeevi as its Chief Scientific Officer
  • Israel Scientific Study: Cannabis Safe and Effective for Regular Use in the Elderly; Can Decrease the Use of Other Prescription Medicines, Including Opioids
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines